A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.
DOI: 10.1200/jco.2026.44.7_suppl.161
文献链接: https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.161
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Rahul Atul Parikh; Benjamin Herzberg; Mark N. Stein; Shumei Kato; Minal A. Barve; David R. Spigel; Benjamin Garmezy; Alexander Philipovskiy; Gopa Iyer; Alissa Jamie Cooper; Manav Korpal; Maciej Cabanski; Carolina Perdomo Ortiz; Ralph Tiedt; Lisa D. Cleary; Tess Schmalbach; Markus Warmuth; Filip Janku; Alexander I. Spira

